Faculty, Staff and Student Publications

Publication Date

7-1-2024

Abstract

The treatment landscape of acute myeloid leukaemia (AML) is evolving rapidly. Venetoclax in combination with intensive chemotherapy or doublets or triplets with targeted or immune therapies is the focus of numerous ongoing trials. The development of mutation-targeted therapies has greatly enhanced the treatment armamentarium, with FLT3 inhibitors and isocitrate dehydrogenase inhibitors improving outcomes in frontline and relapsed/refractory (RR) AML, and menin inhibitors showing efficacy in RR NPM1

Keywords

Humans, Leukemia, Myeloid, Acute, Nucleophosmin, Antineoplastic Combined Chemotherapy Protocols, acute myeloid leukaemia, novel agents, novel combinations, targeted treatment

DOI

10.1111/bjh.19519

PMID

38724457

PMCID

PMC12068000

PubMedCentral® Posted Date

5-12-2025

PubMedCentral® Full Text Version

Author MSS

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.